Clinical Trial: NRG BR008

NRG BR008

Status: Open

A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*) *Her2 Radiation Optimization (HERO)

Eligible for screening study DCP 001